Tango Therapeutics, Inc.

TNGX Healthcare Biotechnology

Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.

Revenue
−100.0%
EPS
−5.71%
Free cash flow
−4.58%

Quarter to June 2026, against a year earlier

21.50 0.63 +3.02%
Market cap
$3.5B
P/E
0.0×
Fwd P/E
−16.1×
Dividend yield
—
F-score
4/9
Altman Z
9.88
Beneish M
n/a
Dividend safety
n/a

Tango Therapeutics, Inc. (TNGX) Gross margin

Alert me on Gross margin

Tango Therapeutics, Inc.'s gross margin over the twelve months to 31 December 2025 was 100.0%. Over the past ten years it has ranged from 100.0% (fiscal 2025) to 100.0% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.

Gross margin, annual

Embed this chart

Annual newest first

Period Gross margin Change (points)
FY2025 100.0% 0.00
FY2024 100.0% 0.00
FY2023 100.0% 0.00
FY2022 100.0% 0.00
FY2021 100.0% 0.00
FY2020 100.0% —

Quarterly newest first

Period Gross margin Change (points)
Dec 2025 0.00% (100.00)
Sep 2025 100.0% 0.00
Jun 2025 100.0% 0.00
Mar 2025 100.0% 0.00
17 more quarters

Against its own ten years

Low 100.0% High 100.0%
Ten-year median 100.0%
Current reading's percentile 100

Gross margin against peers

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on TNGX